Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BTK Inhibitor + Anti-CD19 CAR-T for R/R B-NHL
NCT05744037Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, anti-CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by The Affiliated Hospital of Xuzhou Medical University. Status: unknown.
02
Drugs
ibrutinibanti-CD19 CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05744037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744037.